<DOC>
	<DOCNO>NCT01107964</DOCNO>
	<brief_summary>The investigator hypothesize oral omega-3-acid ethyl ester ( Lovaza , GlaxoSmithKline , Research Triangle Park , NC ) decrease dry-eye related symptom well clinical marker associate dry eye disease ( Schirmer-1 test value , positive vital stain lissamine green , fluorescein tear break-up time ) compare administration placebo .</brief_summary>
	<brief_title>Oral Omega-3 Fatty Acids Treatment Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Age &gt; 18 year Typical symptom dry eye ( photophobia , burning , foreign body sensation , blur vision improve blinking ) Schirmer Test &lt; 8 mm/5 minute Fluorescein tear breakup time &lt; 8 second No current use dry eye treatment ( except artificial lubrication ) Signature consent form Infectious keratoconjunctivitis inflammatory disease unrelated dry eye Eyelid eyelash abnormality Alteration nasolacrimal apparatus Treatment drug affect tear Concomitant ocular therapy Topical ophthalmic steroid take 4 week study Pregnant/breastfeeding woman History liver disease History fish and/or shellfish allergy hypersensitivity History corn allergy hypersensitivity Treatment systemic anticoagulation therapy Patients bleed disorder receive anticoagulation ( e.g. , warfarin , enoxaparin , dipyridamole , clopidogrel )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
	<keyword>Recent Diagnosis Dry Eye Syndrome</keyword>
</DOC>